Molnupiravir - Emory University/Georgia State University/Merck & Co/Ridgeback Biotherapeutics
Alternative Names: EIDD-2801; LAGEVRIO; MK-4482; Molxvir; MovforLatest Information Update: 25 Jul 2024
At a glance
- Originator Emory University; Georgia State University
- Developer Emory University; Hetero Labs; Merck & Co; Merck Sharp & Dohme; Ridgeback Biotherapeutics
- Class Antivirals; Esters; Hydroxylamines; Pyrimidinones; Ribonucleosides; Small molecules
- Mechanism of Action Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed COVID 2019 infections
- Phase II Respiratory syncytial virus infections
- Phase I Influenza virus infections; Renal failure
- No development reported Chikungunya virus infections; Eastern equine encephalomyelitis; Ebola virus infections; Middle East respiratory syndrome coronavirus; Severe acute respiratory syndrome; Venezuelan equine encephalomyelitis
Most Recent Events
- 28 Jun 2024 Merck Sharp & Dohme completes a phase I trial in Influenza virus infections (In volunteers) in United Kingdom (PO) (NCT05818124)
- 28 May 2024 No recent reports of development identified for preclinical development in Ebola-virus-infections in USA (PO)
- 28 May 2024 No recent reports of development identified for preclinical development in Middle-East-respiratory-syndrome-coronavirus(Prevention) in USA (PO)